Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are two of the most valuable healthcare stocks in the world, largely due ...

Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...

Eli Lilly’s popular anti-obesity drug Zepbound could get a sales boost after the U.S. Medicare program decided to pay for its use to treat sleep apnea. The Centers f ...

Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly LLY ...

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

New FDA draft guidance for drugmakers focuses on trial design for developing obesity treatments. Read more here.

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

Eli Lilly will seek to have Mounjaro listed on the scheme this year. If successful, it would mean taxpayer subsidies for the ...

This follows approval from the UK’s health technology assessment body, which evaluates the cost-effectiveness of new treatments. The FDA has approved Eli Lilly’s obesity drug, Zepbound ...

Ricks, Lilly chair and CEO, will participate in a fireside chat on Tuesday, Jan. 14 at 5:15 p.m. Eastern time. Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.